Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans.
Sign Up to like & getrecommendations! Published in 2018 at "Clinical therapeutics"
DOI: 10.1016/j.clinthera.2018.07.011
Abstract: PURPOSE The aim of this article was to describe and compare treatment patterns, health care resource utilization (HRU), and health care costs before and after transition in veterans with schizophrenia who were transitioned from paliperidone… read more here.
Keywords: health care; transition; paliperidone palmitate; pp3m ... See more keywords
Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
Sign Up to like & getrecommendations! Published in 2017 at "Neuropsychiatric Disease and Treatment"
DOI: 10.2147/ndt.s150568
Abstract: Aims Paliperidone palmitate 3-month (PP3M) represents a new long-acting injectable antipsychotic therapeutic option. This review aims: 1) to summarize available data relating to efficacy, safety, tolerability and costs of PP3M; 2) to describe hospitalization rate,… read more here.
Keywords: long acting; treatment; safety; monthly long ... See more keywords
Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Psychiatry"
DOI: 10.3389/fpsyt.2023.1130636
Abstract: Introduction Long-acting injectable antipsychotics (LAIs) have proven to be effective in the maintenance treatment of patients suffering from schizophrenia, and their safety and tolerability profiles represent a key factor in their long-term use and choice… read more here.
Keywords: safety; tolerability; paliperidone palmitate; analysis ... See more keywords